CPP-directed oligonucleotide exon skipping in animal models of Duchenne muscular dystrophy

Area of Science:

• * Molecular Biology
• * Genetic Medicine
• * Pharmacology

Background:

• * Antisense oligonucleotides (AOs) are utilized as splice-switching agents to modify disease progression by altering gene exon inclusion or exclusion.
• * Duchenne muscular dystrophy (DMD), a severe muscle degenerative disease, can be targeted by AO-mediated exon skipping to restore the dystrophin protein and ameliorate the phenotype.
• * Recent Phase I clinical trials demonstrated proof-of-concept for local intramuscular AO treatments in DMD.

Purpose of the Study:

• * To review the background of AO technology for splice switching.
• * To detail experimental protocols for investigating cell-penetrating peptide (CPP)-conjugated AOs.
• * To assess the potential of CPP-conjugated AOs for systemic delivery and therapeutic correction in DMD animal models.

Main Methods:

• * Review of existing literature on AO-mediated splice switching and DMD therapeutics.
• * Description of experimental protocols for developing and testing CPP-conjugated AOs.
• * Focus on systemic delivery strategies for AO-based therapies in DMD animal models.

Main Results:

• * AO-mediated exon skipping can restore the DMD open reading frame and produce functional dystrophin in animal models.
• * Cell-penetrating peptide (CPP) conjugation enhances the potential for systemic delivery of AOs.
• * Promising results have been observed in DMD animal models using CPP-conjugated AOs for therapeutic correction.

Conclusions:

• * Systemic AO delivery protocols are crucial for advancing DMD treatment beyond local applications.
• * CPP-conjugated AOs represent a promising strategy for effective systemic delivery and splice correction in DMD.
• * Further investigation into CPP-conjugated AOs is warranted for developing systemic therapies for DMD.